<DOC>
	<DOCNO>NCT02567656</DOCNO>
	<brief_summary>The purpose study evaluate safety , PK efficacy RP6530 , dual PI3K delta/gamma inhibitor patient relapse refractory T-cell Lymphoma .</brief_summary>
	<brief_title>Safety Efficacy Study Dual PI3K Delta/Gamma Inhibitor T-cell Lymphoma</brief_title>
	<detailed_description>Safety : Treatment-Emergent AE ; Treatment-Related AE , SAE Clinical significant AE ; Dose Limiting Toxicities ( DLT ) . PK : Peak Plasma Concentration ( Cmax ) , Area plasma concentration versus time curve ( AUC ) , Time Maximum concentration observe ( Tmax ) . Efficacy : Overall Response Rate ( ORR ) , Progression Free Survival ( PFS ) , Overall Survival ( OS ) Duration Response .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Refractory relapse least 1 prior treatment line . ECOG performance status ≤2 Patients must ≥18 year age Able give write informed consent . Any cancer therapy last 3 week limit palliative radiation &lt; 2 week Patients HBV , HCV HIV infection Previous therapy GS1101 ( CAL101 , Idelalisib ) , IPI145 ( Duvelisib ) , TGR1202 drug specifically inhibit PI3K/ mTOR ( include temsirolimus , everolimus ) , AKT BTK Inhibitor ( include Ibrutinib ) last 6 month Patients immunosuppressive therapy include systemic corticosteroid . Patients known history liver disorder . Patients uncontrolled Diabetes Type I Type II Any severe and/or uncontrolled medical condition condition could affect participation study . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CTCL</keyword>
	<keyword>PTCL</keyword>
	<keyword>RP6530</keyword>
</DOC>